Mulmit

Intellia Therapeutics, Inc.Intellia Therapeutics, Inc.

NTLA Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-3167,671,000-440,990,000-412,694,000-3.81
2024-12-3157,877,000-534,263,000-519,021,000-5.25
2023-12-3136,275,000-515,291,000-481,192,000-5.42
2022-12-3152,121,000-458,164,000-474,186,000-6.16
2021-12-3133,053,000-267,850,000-267,892,000-3.78

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-08-21LEONARD JOHN MPresident and CEO2,785
2026-08-20LEONARD JOHN MPresident and CEO19,890
2026-07-22Dulac Edward J IIIEVP, Chief Financial Officer8,111
2026-07-02Dulac Edward J IIIEVP, Chief Financial Officer4,677
2026-07-01Dube Michael PVP, Chief Accounting Officer2,641
2026-06-09GOODMAN JESSE9,200
2026-06-09GOODMAN JESSE13,300
2026-06-09CHASE WILLIAM J9,200
2026-06-09CHASE WILLIAM J13,300
2026-06-09Verwiel Frank9,200
2026-06-09Verwiel Frank13,300
2026-06-09Keresty Georgia9,200

8-K events

FiledItems
2026-09-08Regulation FD disclosure · Other events · Financial statements and exhibits
2026-09-04Entry into a material agreement · Creation of a direct financial obligation · Regulation FD disclosure · Financial statements and exhibits
2026-08-06Results of operations · Financial statements and exhibits
2026-06-15Regulation FD disclosure · Other events · Financial statements and exhibits
2026-06-10Submission of matters to a vote
2026-05-11Results of operations · Financial statements and exhibits
2026-04-30Entry into a material agreement · Results of operations · Financial statements and exhibits
2026-04-27Regulation FD disclosure · Other events · Financial statements and exhibits
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

In Vitro & In Vivo Diagnostic Substances — 같은 업종, 그리고 규모가 비슷한 기업In Vitro & In Vivo Diagnostic Substances — and other companies of a similar size

SEC가 같은 업종(In Vitro & In Vivo Diagnostic Substances)으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (In Vitro & In Vivo Diagnostic Substances) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.

한국 시장 대시보드Korea dashboard 미국·글로벌 대시보드US & Global dashboard